Replies to post #52 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC had $254.1M of cash at 12/31/15: #msg-120921973.

[DewDiligence]

Dosing info in cervical dystonia (from today’s 1Q16 CC):

Above info from $RVNC 1Q16 CC today. CD = cervical dystonia.

— Roy Friedman (@DewDiligence) May 9, 2016

[DewDiligence]

RVNC had $236.6M of cash at 3/31/16 (a reduction of $17.5M relative to 12/31/15):

http://finance.yahoo.com/news/revance-releases-first-quarter-2016-200500014.html

Cash-usage guidance for 2016 remains unchanged at $105-115M.

[DewDiligence]

RVNC discontinues development of RT001 (topical): #msg-123277118.